LIVERFASt (L-FAST) Identifies Advanced (F3F4, AF) and Clinically Significant Fibrosis (F2-F4, CSF) in MASLD Patients

LIVERFASt (L-FAST) Identifies Advanced (F3F4, AF) and Clinically Significant Fibrosis (F2-F4, CSF) in MASLD Patients

In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4 advanced fibrosis cases, outperforming FIB-4 + Fibroscan. Notably, 74% of F3–F4 patients had FIB-4 scores below 2.67, showing LIVERFASt’s value in addressing the limitations of indeterminate zones in traditional scoring.

Scroll to Top

Contact Us

We are always ready to help you with your liver problems

For clinical and medical enquiries, contact us at: medicalaffairs@fibronostics.com